---
title: Stem Cell Transplant Basics
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Huppert's Notes]]

# Stem Cell Transplant Basics

## Types of hematopoietic stem cells (HSCs):

### Autologous:
* own HSCs to â€œrescueâ€ the bone marrow after high intensity chemotherapy
* Uses: Multiple myeloma, some lymphomas, germ cell tumors

### Allogeneic:
* donor (non-self) HSCs to replace the bone marrow after high-intensity chemotherapy AND for graft vs. tumor effect
* Uses: AML, ALL, CML, CLL

## Sources of cells:

### Peripheral blood stem cells:
The donor is given a growth factor (e.g., G-CSF, GM-CSF) to mobilize HSCs from the bone marrow and then peripheral blood is collected. Less invasive, lower risk for the donor.

-Â Â Â Bone marrow: Bone marrow aspirated from the iliac crests

-Â Â Â Umbilical cord: Umbilical cord blood has a high number of HSCs. However, there is only a limited amount of blood if engraftment fails.

*Â Â Â Matching for allogeneic transplant:

-Â Â Â For allogeneic transplants, where non-self cells are given to a patient, donors are tested by HLA matching. There are 12 HLA alleles that are tested with a â€œ12/12â€ match being the best match.

-Â Â Â Potential donors:

*****Â Â Â Identical twin: Ideal source as they will be a 12/12 match in addition to matching on other alleles and antigens not tested

*****Â Â Â Matched related donor (MRD): Ideally a sibling

*****Â Â Â Matched unrelated donor (MURD)

*Â Â Â Side effects: For autologous and identical twin allogeneic transplants, will not develop GVT or GVHD

-Â Â Â Graft vs. tumor: Desired therapeutic side effect where the transplanted T-cells recognize the tumor cells as foreign and immunologically attack the tumor cells

-Â Â Â Graft vs. host disease (GVHD): Undesired side effect where the transplanted T-cells attack the hostâ€™s cells, causing an autoimmune syndrome. Most common sites: Skin, liver, GI tract.

*****Â Â Â Acute: Within 100 days of transplant

*****Â Â Â Chronic: >3 months after transplant, but can occur at any time

*****Â Â Â Prophylaxis: Patients receive immunosuppressive medicines to prevent graft rejection and prevent GVHD, such as tacrolimus, sirolimus, mycophenolate, methotrexate, post-transplant cyclophosphamide

*****Â Â Â Treatment: Depends on the timing and severity of GVHD. Treatment usually includes increasing immunosuppressive regimens and steroids.

